Related Experiment Video

Updated: Jul 30, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K

Management of Advanced Prostate Cancer in the Precision Oncology Era

Claire M Gillette1, Gabriel A Yette1, Scott D Cramer1

  • 1Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

Cancers
|May 13, 2023
PubMed

Insights

Precision oncology advances, including biomarker-driven therapies like PD-1 inhibitors and PARP inhibitors, are revolutionizing prostate cancer (PC) treatment. PSMA-targeted theranostics offer new hope for metastatic castration-resistant prostate cancer (mCRPC).

Area of Science:

  • Oncology
  • Precision Medicine
  • Radiopharmaceutical Therapy

Background:

  • Prostate cancer (PC) is a leading cause of cancer death in men.
  • Metastatic castration-resistant prostate cancer (mCRPC) remains incurable, necessitating novel therapeutic strategies.
  • Recent advancements in systemic therapies and precision oncology offer new hope for patients with advanced PC.

Purpose of the Study:

  • To review seminal clinical data supporting new precision oncology therapeutics for PC.
  • To explore the limitations, utility, and potential of these novel treatments.
  • To detail recent advances in biomarker-driven therapies and theranostics for PC.

Main Methods:

  • Review of clinical data for precision oncology therapeutics in prostate cancer.
  • Analysis of biomarker-driven therapies, including PD-1 inhibitors and PARP inhibitors.
  • Evaluation of theranostic agents, such as PSMA-targeted radioligand therapies.

Main Results:

  • Biomarker-driven therapies are bringing precision oncology closer to reality for all PC patients.
  • Tumor-agnostic approval of pembrolizumab (PD-1 inhibitor) signifies a major step forward.
  • PSMA-targeted theranostics are transforming PC diagnosis and treatment, with recent FDA approvals for mCRPC.

Conclusions:

  • Precision-based oncology has significantly advanced the treatment landscape for prostate cancer.
  • Theranostic agents and biomarker-driven therapies represent key innovations in managing advanced and metastatic PC.
  • Continued research and application of these precision approaches hold promise for improving outcomes in PC.
Keywords:
PARP inhibitorsPSMAadvanced prostate cancerbiomarkerschemotherapygenomic selectionimmunotherapymetastatic prostate cancerradioligand therapytheranostics

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

717

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K